Provide strategic consulting services to small and mid-sized enterprises (SMEs) focused on healthcare, life sciences, biopharma, specialty pharma, vaccines, and diagnostic companies.
• Lead Private Equity (PE) backed Allergy Practice with acquisition and growth strategy, plus Non-Director Board Member, and Industry Advisor delivering guidance on strategy.
• Expanded European companies into North American markets as part of a consulting contract with $6B Life Sciences Private Equity Asset Portfolio firm (Archimed).
• Assisted Fluent (a Beekman PE Portfolio Company), serving the Dental Analytics and Informatics market with commercial strategy & new business growth initiatives.
• Served as Senior Advisor to a private digital healthcare and food allergy startup with respect to acquisition, commercial, and strategic plans.
• Drove Ex-USA Market opportunities for Medical Device company, assisting with market expansion into Europe, Latin America, and Asia, including identification, due d

Restructured a direct to physician business model driven by price and low margins, into a value-added profitable specialty pharma business with double digit growth. Grew business from $7M to $110M in sales and -4% to +25% EBITDA with CAGR of 14% over period. 2 OF 3

Responsible for the P&L of N. America for ALK's Biopharma business. B2B sales via buy & bill and Rx products into the Allergists, ENT and selected Pediatricians plus GP's.

Transformed negative EBITDA business into a profitable commercial platform by expanding sales from Allergists to more ENTs, Pediatricians, PCPs, and Hospital markets. Cultivated a strong leadership team and business development/hunter sales mindset.
• Grew business from $20M to around $60M (organic CAGR of 11% and 15% CAGR with acquisitions), establishing a long-term platform for continued growth and profitability.
• Integrated and acquired Canadian Distributor, USA Vet Allergy business, and Compounding Pharmacy, yielding an additional $13M in sales while diversifying the business to higher margin segments.

Led Biologics (Buy & Bill), medical billing business that was restructured and generated growth of over 15% CAGR. Restructured sales force into effective business development and value-added selling team. Grew from $7M to around $20M.
• Completely revamped and changed the selling process & sales training, replacing over 60% of the sales force in the first 6 months, while transforming the business from price focused to value driven technology leader.
• Drove a multi-million-dollar joint venture focused on selling in-vivo diagnostics into Hospital Infectious Disease Units, resulting in $10M in revenue and CAGR 15%.
• Attained rights to only FDA approved in-vivo diagnostics Penicillin allergy skin testing, launching product into new Hospital Infectious Disease segment and Allergy markets. Grew business from startup into an $8M, 30% EBITDA stand-alone profit center.